Isocitrate Dehydrogenase 1/IDH1 Antibody (843219) [Alexa Fluor™ Plus 488]

• Reactivity: Hu
• Clone: 843219
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor Plus 488

Isocitrate Dehydrogenase 1/IDH1 Antibody (843219) [Alexa Fluor™ Plus 488] Summary

• Specificity: Detects human Isocitrate Dehydrogenase 1/IDH1 in ELISAs and Western blots.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Isocitrate Dehydrogenase 1/IDH1 Antibody (843219) [Alexa Fluor™ Plus 488]

• Cytosolic NADP-isocitrate dehydrogenase
• EC 1.1.1.42
• IDCD
• IDH
• IDH1
• IDP
• IDPC
• isocitrate dehydrogenase [NADP] cytoplasmic
• isocitrate dehydrogenase 1 (NADP+), soluble
• Isocitrate Dehydrogenase 1
• NADP(+)-specific ICDH
• NADP-dependent isocitrate dehydrogenase, cytosolic
• NADP-dependent isocitrate dehydrogenase, peroxisomal
• Oxalosuccinate decarboxylase
• PICD

Background

Isocitrate Dehydrogenase 1 (IDH1) catalyzes the oxidative decarboxylation of isocitrate to alpha ‑ketoglutarate. There are two subclasses in the IDH family, one of them utilizing NADP⁺ as the electron acceptor and the other using NAD⁺ (1). The protein encoded by this gene is the NADP⁺-dependent isocitrate dehydrogenase found in the cytoplasm and peroxisomes. In peroxisomes, IDH1 generates the NADPH required for intraperoxisomal reduction reactions. Mutations of Arg132 of human IDH1 result in a reduced ability of the enzyme to convert isocitrate to alpha ‑ketoglutarate, but the enzyme acquires the ability to generate 2-hydroxyglutarate (2HG) from  alpha ‑ketoglutarate (2). Elevated levels of the metabolite 2HG are associated with a high risk of malignant brain tumors. Arg132 mutations of IDH1 are common in high‑grade gliomas, but not in other types of tumors (3).

1. Nekrutenko, A. et al. (1998) Mol. Biol. Evol. 15:1674.
2. Dang, L. et al. (2009) Nature 462:739.
3. Bleeker, F.E. et al. (2009) Hum. Mutat. 30:7.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.